Eli Lilly is facing $165 million in charges and development milestones from the U.S. Securities and Exchange Commission (SEC). The charges come from several in-process research and development projects acquired outside of a business combination.
The U.S. Transportation Security Administration (TSA) proposed more than 900 civil penalty fines and 2,700 warning notices against maskless passengers since February 2021, a government report issued March 14 said.
Martin Shkreli received his second lifetime ban from the pharmaceutical industry. One month after U.S. District Court Judge Denise Cotes banned the “Pharma Bro” from future involvement in the industry, a second judge handed down a similar order and ordered him to pay a $1.39 million fine.
A lawyer for the European Union accused AstraZeneca on May 26 of failing to respect the company’s contract with the 27-nation bloc for the supply of Covid-19 vaccines and asked a Belgian court to impose a large fine on the Anglo-Swedish drug firm.
The cancer drugmaker pled guilty of violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to investigators in federal court.
U.S. prosecutors are pursuing possible penalties of nearly $13 billion to resolve investigations of OxyContin maker Purdue Pharma after uncovering evidence of criminal and civil misconduct stemming from the company’s alleged role in fueling the nation’s opioid crisis, people familiar with the matter said.
Less than a year after Sandoz, the generics arm of Novartis, vowed to fight allegations of being involved in a scheme to manipulate the price of generic drugs along with other drugmakers, the company changed course and agreed to pay a $195 million penalty to the U.S. government.
An Oklahoma judge ordered Johnson & Johnson to pay $572.1 million to the state for the company’s part in fueling an opioid epidemic by deceptively marketing addictive painkillers, a sum substantially less than investors expected, driving up J&J shares.
The Philippines suspended clearance for Sanofi’s dengue vaccine Dengvaxia and fined the French drugmaker.
Pfizer has been slapped with a $107 million fine in Britain for a price increase of its epilepsy drug. The fine was levied by Britain’s Competition and Markets Authority.